Patents Examined by Wu-Cheng Winston Shen
  • Patent number: 9163044
    Abstract: Provided herein are novel carbon-monoxide releasing molecules (CO-RMs) of the Formula (I): and esters, amides, salts, solvates and hydrates thereof; wherein R1 and R2 are as described herein. Also provided are pharmaceutical compositions comprising these compounds, methods of their preparation, and their use in the treatment of liver disease and inflammation.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: October 20, 2015
    Assignee: Alfama, Inc.
    Inventors: Walter Anton Blättler, Carlos J. R. C. Romão, Sandra Sofia Pereira Rodrigues, Lukas Adrian Kromer, Leo Edmond Otterbein, David John Gallo
  • Patent number: 9155740
    Abstract: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: October 13, 2015
    Inventors: Richard J. Johnson, Takahiko Nakagawa
  • Patent number: 9149483
    Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 6, 2015
    Assignee: GALERA LABS, LLC
    Inventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
  • Patent number: 9149467
    Abstract: The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: October 6, 2015
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Bing Li, Yunde Xie, Xinbo Zhou
  • Patent number: 9149532
    Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: October 6, 2015
    Assignee: Daiichi Sanykyo Company, Limited
    Inventors: Masazumi Kojima, Yoshio Kuno, Hiroaki Nakagami, Shinji Sagasaki, Koichi Ishidoh, Gaku Sekiguchi
  • Patent number: 9138404
    Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: September 22, 2015
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Amy Dix Rock
  • Patent number: 9133184
    Abstract: The present application discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the application discloses the use of these compounds, a method for therapy and to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: September 15, 2015
    Assignee: ANIONA APS
    Inventors: Dan Peters, Gordon Munro, Elsebet Ostergaard Nielsen, Karin Sandager Nielsen
  • Patent number: 9132084
    Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: September 15, 2015
    Assignee: NEOTHETICS, INC.
    Inventors: John Daniel Dobak, Kenneth Walter Locke
  • Patent number: 9125809
    Abstract: There is disclosed a technique for making a jelly formulation comprising pectin slide out of a container easily (improving the slidability of the jelly formulation) when taking the formulation out of the container to prevent the formulation from remaining in the container. The jelly formulation of the present invention comprises a drug, pectin, divalent metal ions, and polyoxyethylene polyoxypropylene glycol.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: September 8, 2015
    Assignee: NICHI-IKO PHARMACEUTICAL CO., LTD.
    Inventors: Yoichiro Goto, Kurato Takanashi, Teruo Maruta, Masatake Dairaku
  • Patent number: 9120754
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: September 1, 2015
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Patent number: 9114068
    Abstract: Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: August 25, 2015
    Assignee: Cumberland Pharmaceuticals, Inc.
    Inventors: Leo Pavliv, Amy Dix Rock
  • Patent number: 9095515
    Abstract: This invention is a novel pharmaceutical composition of ezetimibe or a pharmaceutically acceptable salt thereof comprising one or more pharmaceutically acceptable excipients having high bioavailability with improved solubility and dissolution rate which is stable throughout the shelflife, methods for their preparation, and methods for treatment using the same.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: August 4, 2015
    Assignee: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Umit Cifter, Levent Oner, Ali Turkyilmaz, Ibrahim Murat Uzer, Gaye Ramazanoglu
  • Patent number: 9095581
    Abstract: This invention concerns combinations of inhibitors of MEK, Raf protein kinases, and other kinases including VEGFR1-3 and PDGFR-?. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer and other hyperproliferative disorders.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: August 4, 2015
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jeffrey N. Miner, Mark S. Chapman, Barry Quart, Alex Adjei, Chunrong Yu
  • Patent number: 9096612
    Abstract: The present invention relates to a fused heterocyclic derivative of the formula (I) The variables R1-R4, z, A, Q, X and Y are as defined in the claims. The following heterocycles are exemplified sub-structures of formula (I): The compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor), More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of cognitive disorders, age-relate cognitive decline and dementia.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: August 4, 2015
    Assignees: AbbVie B.V., AbbVie Inc.
    Inventors: Pieter Smid, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Leonardus A. J. M. Sliedregt, Maria J. P. van Dongen, Jacobus A. J. den Hartog, Adrian Hobson
  • Patent number: 9090603
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: July 28, 2015
    Assignee: SYNTA PHARMACEUTICALS CORPORATION
    Inventors: Lijun Sun, Christopher Borella, Hao Li, Jun Jiang, Shoujun Chen, Keizo Koya, Takayo Inoue, Zhenjian Du, Kevin Foley, Yaming Wu, Mei Zhang, Weiwen Ying
  • Patent number: 9078885
    Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: July 14, 2015
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Patent number: 9078889
    Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: July 14, 2015
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Michael T. Nordsiek, Jefferson J. Gregory
  • Patent number: 9073878
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 7, 2015
    Assignee: Zenith Epigenetics Corp.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • Patent number: 9066970
    Abstract: The present invention relates to pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrins as well as their use as osmotic agents, in particular for use in dialysis therapy.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 30, 2015
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Thomas Fichert, Johannes Gerber, Ingo Bichlmaier
  • Patent number: 9060939
    Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: June 23, 2015
    Assignee: Ferring B.V.
    Inventors: Keith A. Moore, Ralph A. Heasley, Jeffrey S. Greiwe, John W. Facemire, Jason D. Modest